In this study, we designed a series of multivalent Rha‐modified nanobody conjugates with the aim to further optimize the ability of nanobody‐based antibody‐recruiting molecules to recruit endogenous antibodies, which would promote the cancer cell killing by the innate immune cells. Here, DHX9 is linked to cancer.